[1」杨文涛，薛卫成，卞修武,等.肿瘤病理诊断规范(乳腺癌)[J.中华病理学杂志,2016,45(8): 525-528.   
[2］《乳腺癌HER2检测指南（2019版）》编写组.乳腺癌HER2检测指南（2019版)[J].中华病理学 杂志,2019,48(3):169-175.   
［3］中国临床肿瘤学会乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会．人表皮生长因子受体2 阳性乳腺癌临床诊疗专家共识(2021版)[J].中华医学杂志，2021,101(17):1226-1231.   
[ 4 ] TARANTINO P, HAMILTON E, TOLANEY SM, et al. HER2-Low breast cancer: pathological and clinical landscape [J]. J Clin Oncol, 2020, 38 (17): 1951-1962.   
[ 5 ］  ALLISON KH, HAMMOND M, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update [J]. J Clin Oncol, 2020, 38 (12): 1346-1366.   
[6] NIELSEN TO, LEUNG S, RIMM DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group [J]. J Natl Cancer Inst, 2021, 113 (7): 808-819. 
[7]《乳腺癌新辅助治疗的病理诊断专家共识（2020版）》编写组.乳腺癌新辅助治疗的病理诊断专 家共识(2020版)[J].中华病理学杂志，2020,49(4):296-304.   
[8] VAN RAMSHORST MS, VAN DER VOORT A, VAN WERKHOVEN ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2- positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial [J]. Lancet  Oncol, 2018, 19 (12): 1630-1640.  
[ 9 ］ HURVITZ SA, MARTIN M, JUNG KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase II KRISTINE Study [J]. J Clin Oncol, 2019, 37 (25): 2206-2216.   
[ 10 ］  GIANNI L, PIENKOWSKI T, IM YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial [J]. Lancet Oncol, 2016, 17 (6): 791-800.   
[11  SHAO Z, PANG D, YANG H, et al. Efficacy, safety, and tolerability of pertuzumab,trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial [J]. JAMA Oncol, 2020, 6 (3): e193692.   
: 12 ] SLAMON D, EIERMANN W, ROBERT N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med, 2011, 365 (14): 1273-1283.   
[ 13 ］ UNTCH M, JACKISCH C, SCHNEEWEISS A, et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto [J]. J Clin Oncol, 2019, 37 (25): 2226-2234.   
[ 14 ］ VON MINCKWITZ G, HUANG CS, MANO MS, et al. Trastuzumab emtansine for residual invasive her2- positive breast cancer [J]. N Engl J Med, 2019, 380 (7): 617-628.   
15 ］ MARTIN M, HOLMES FA, EJLERTSEN B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebocontrolled, phase 3 trial [J]. Lancet Oncol, 2017, 18 (12): 1688-1700.   
[16] ZHANG L, WU ZY, LI J, et al. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): results from a multicenter, randomized controlled, open-label phase II trial [J]. Int J Cancer, 2022, 150 (4): 654- 662.   
[17］  SCHMID P, CORTES J, PUSZTAI L, et al. Pembrolizumab for early triple-negative breast cancer [J]. N Engl J Med, 2020, 382 (9): 810-821.   
[18 ] TUTT A, GARBER JE, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1-or BRCA2- mutated breast cancer [J]. N Engl J Med, 2021, 384 (25): 2394-2405.   
[19］ SPARANO JA, GRAY RJ, MAKOWER DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [J]. N Engl J Med, 2018, 379 (2): 111-121.   
[ 20 ］ KALINSKY K, BARLOW WE, GRALOW JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer [J]. N Engl J Med, 2021, 385 (25): 2336-2347.   
[ 21 ］ CARDOSO F, VAN'T VEER LJ, BOGAERTS J, et al. 7O-gene signature as an aid to treatment decisions in early-stage breast cancer [J]. N Engl J Med, 2016, 375 (8): 717-729.   
[ 22 ］ VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer [J]. N Engl J Med, 2017, 377 (2): 122-131.   
[ 23 ］  PEREZ EA, ROMOND EH, SUMAN V J, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analy-sis of overall survival from NSABP B-31 and NCCTG N9831 [J]. J Clin Oncol, 2014, 32 (33): 3744-3752.   
[ 24 ］ JONES SE, COLLEA R, PAUL D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study [J]. Lancet Oncol, 2013, 14 (11): 1121-1128.   
[25 ] TOLANEY SM, GUO H, PERNAS S, et al. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer [J]. J Clin Oncol, 2019, 37 (22): 1868-1875.   
[ 26 ] MACKEY JR, PIEnKOWSKI T, CROWN J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial [J]. Ann Oncol, 2016, 27 (6): 1041-1047.   
[ 27 ]  YU KD, YE FG, HE M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical Trial [J]. JAMA Oncol, 2020, 6 (9): 1390- 1396.   
[ 28 ］ JONES S, HOLMES FA, O'SHAUGHNESSY J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year FollowUp of US Oncology Research Trial 9735 [J]. J Clin Oncol, 2009, 27 (8): 1177-1183.   
[ 29 ］  NITZ U, GLUZ O, CLEMENS M, et al. West german study planb trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2- negative early breast cancer [J]. J Clin Oncol, 2019, 37 (10): 799-808.   
[ 30 ] WANG X, WANG SS, HUANG H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triplenegative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial [J]. JAMA, 2021, 325 (1): 50-58.   
[ 31   WANG S, Li J, JIANG Z, et al. Breast cancer patients with low estrogen receptor expression gain no significant survival benefit from endocrine therapy: a real-world study from China [J]. Transl Breast Cancer Res, 2020, 1: 14.   
[ 32 ］ REGAN M M, NEVEN P, GIOBBIE-HURDER A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8. 1 years median follow-up [J]. Lancet Oncol, 2011, 12 (12): 1101- 1108.   
[33 ] GOSS PE, INGLE JN, PATER JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen [J]. J Clin Oncol, 2008, 26 (12): 1948-1955.   
[34] TJAN-HEIJNEN V, VAN HELLEMOND I, PEER P, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial [J]. Lancet Oncol, 2017, 18 (11): 1502-1511.   
[ 35 ］ JOHNSTON S, HARBECK N, HEGG R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR $^{+}$ , HER2-, node-positive, high-risk, early breast cancer (MonarchE)[J]. J Clin Oncol, 2020, 38 (34): 3987-3998.   
[ 36 ］ GOSS PE, INGLE JN, PRITCHARD KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years [J]. N Engl J Med, 2016, 375 (3): 209-219.   
[37］ PAGANI O, FRANCIS PA, FLEMING GF, et al. SOFT and TEXT Investigators and International Breast Cancer Study Group. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT [J]. J Clin Oncol, 2020, 38 (12): 1293-1303.   
[ 38 ] PAGANI O, REGAN MM, WALLEY BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [J]. N Engl J Med, 2014, 371 (2): 107-118.   
[ 39 ］ REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute benefit of adjuvant endocrine thera-pies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials [J]. J Clin Oncol, 2016, 34 (19): 2221-2231.   
[ 40 ］ DAVIES C, PAN H, GODWIN J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J]. Lancet, 2013, 381 (9869): 805-816.   
[ 41 ] SJOSTROM M, CHANG SL, HARTMAN L, et al. Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery [J]. J Clin Oncol, 2021, 39 (15 $-$ suppl): 512.   
[ 42 ]  CHEVLI NC, HAQUE W, TRAN KT, et al. Role of 21-gene recurrence score in patients age $\geqslant70$ with T1NOER/PR $^{+}$ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy [J]. J Clin Oncol, 2021, 39: 571.   
[ 43 ]  WANG SL, FANG H, HU C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China [J]. J Clin Oncol, 2020, 38 (31): 3604-3614.   
[ 44 ］ CORREA C, HARRIS EE, LEONARDI MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement [J]. Pract Radiat Oncol, 2017, 7 (2): 73-79.   
[45] WHELAN TJ, JULIAN JA, BERRANG TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial [J]. Lancet, 2019, 394 (10215): 2165-2172.   
[46 ］ MEATTINI I, MARRAZZO L, SAIEVA C, et al. Accelerated partial-breast irradiation compared with  whole-breast irradiation for early breast cancer: long-term results of the randomized phase Il APBIIMRT-Florence trial [J]. J Clin Oncol, 2020, 38 (35): 4175-4183.   
[ 47 ］  MCGALE P, TAYLOR C, CORREA C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials [J]. Lancet, 2014, 383 (9935): 2127-2135.   
[48 ] KIM YB, BYUN HK, KIM DY, et al. Effect of elective internal mammary node irradiation on diseasefree survival in women with node-positive breast cancer: a randomized phase 3 clinical trial [J]. JAMA Oncol, 2022, 8 (1): 96-105.   
[49 ] ZHANG L, ZHOU M, LIU Y, et al. Is it beneficial for patients with pT1-2N1MO breast cancer to receive postmastectomy radiotherapy?An analysis based on Recurlndex assay [J]. Int J Cancer, 2021, 149 (10): 1801-1808.   
[ 50 ］ MURRAY BRUNT A, HAVILAND JS, WHEATLEY DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial [J]. Lancet, 2020, 395 (10237): 1613-1626.   
[51］ DONKER M, VAN TIENHOVEN G, STRAVER ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial [J]. Lancet Oncol, 2014, 15 (12): 1303- 1310.   
[52］ JIANG Z, WANG H, WANG S, et al. Chinese expert consensus statement on the clinical diagnosis and treatment of breast cancer bone metastasis and bone related disease [J]. Transl Breast Cancer Res, 2021, 2: 2.   
[ 53 ] SWAIN S M, BASELGA J, KIM S B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-posi-tive metastatic breast cancer [J]. New Engl J Med, 2015, 372 (8): 724-734.   
[ 54  WARDLEY A M, PIVOT X, MORALES-VASQUEZ F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2- positive metastatic breast cancer [J]. J Clin Oncol, 2010, 28 (6): 976-983.   
[55 ］ ROBERT N, LEYLAND-JONES B, ASMAR L, et al. Randomized phase ⅢI study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2- overexpressing metastatic breast cancer [J]. J Clin Oncol, 2006, 24 (18): 2786-2792.   
[ 56 ］ YAN M, BIAN L, HU X, et al. Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, doubleblind, placebo-controlled phase 3 study [J]. Transl Breast Cancer Res, 2020, 1: 13.   
[57］ XU B, YAN M, MA F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, openlabel, randomised, controlled, phase 3 trial [J]. Lancet Oncol, 2021, 22 (3): 351-360.   
[58 ］ MA F, OUYANG Q, LI W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive  metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II Study [J]. J Clin Oncol, 2019, 37 (29): 2610-2619.   
[ 59 ］ VERMA S, MILES D, GIANNI L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer [J]. N Engl J Med, 2012, 367 (19): 1783-1791.   
[ 60 ] SAURA C, OLIVEIRA M, FENG YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with $\geqslant~2$ HER2-directed regimens: Phase II NALA Trial [J]. J Clin Oncol, 2020, 38 (27): 3138-3149.   
[61 ］ CAMERON D, CASEY M, PRESS M, et al. A phase Ml randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses [J]. Breast Cancer Res Treat, 2008, 112 (3): 533- 543.   
[62 ］ VON MINCKWITZ G, DU BOIS A, SCHMIDT M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study [J]. J Clin Oncol, 2009, 27 (12): 1999-2006.   
[63 ］ RUGO HS, IM SA, CARDOSO F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated erbb2-positive advanced breast cancer: a phase 3 randomized clinical trial [J]. JAMA Oncol, 2021, 7 (4): 573-584.   
[ 64 ］ MURTHY RK, LOI S, OKINES A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer [J]. N Engl J Med, 2020, 382 (7): 597-609.   
[65 ］ MODI S, SAURA C, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2- positive breast cancer [J]. N Engl J Med, 2020, 382 (7): 610-621.   
[66］中国临床肿瘤学会乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会．人表皮生长因子受体 2阳性乳腺癌临床诊疗专家共识(2021版)[J].中华医学杂志，2021,101(17):1226-1231.   
[ 67 ] HUA X, BI XW, ZHAO JL, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as Firstline Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)[J]. Clin Cancer Res, 2022, 28 (4): 637-645.   
[68］边莉，徐兵河，邸立军，等.重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转 移性乳腺癌随机对照Ⅲ期临床研究[J].中华医学杂志，2020,100(30):2351-2357.   
[ 69 ］ XU B, ZHANG Q, SUN T, et al. Efficacy, safety, and immunogenicity of HLXO2 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase II Equivalence tria [J]. BioDrugs, 2021, 35(3): 337-350.   
[ 70 ］ SEIDMAN AD, TIERSTEN A, HUDIS C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer [J]. J Clin Oncol, 1995, 13 (10): 2575-2581.   
[71 ］ PEREZ EA, VOGEL CL, IRWIN DH, et al. Multicenter phase I trial of weekly paclitaxel in women with metastatic breast cancer [J]. J Clin Oncol, 2001, 19 (22): 4216-4223.   
[ 72 ] MAVROUDIS D, PAPAKOTOULAS P, ARDAVANIS A, et al. Randomized phase Il trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer [J]. Ann Oncol, 2010, 21 (1): 48-54.   
[73 ］ BAJETTA E, PROCOPIO G, CELIO L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women [J]. J Clin Oncol, 2005, 23 (10): 2155-2161.   
[ 74 ］ SEIDMAN AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer [J]. Oncology (Williston Park), 2001, 15 (2 Suppl 3): 11-14.   
[ 75 ］ ZELEK L, BARTHIER S, RIOFRIO M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma [J]. Cancer, 2001, 92 (9): 2267- 2272.   
[76］ O'SHAUGHNESSY J, SCHWARTZBERG L, DANSO MA, et al. Phase Il study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triplenegative breast cancer [J]. J Clin Oncol, 2014, 32 (34): 3840-3847.   
[77 ] HU XC, ZHANG J, XU BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, openlabel, multicentre, phase 3 trial [J]. Lancet Oncol, 2015, 16 (4): 436-446.   
[78 ] MORGAN GJ, GREGORY WM, DAVIES FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis [J]. Blood, 2012, 119 (1): 7-15.   
[ 79 ] CORTES J, CESCON DW, RUGO HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial [J]. Lancet, 2020, 396 (10265): 1817-1828.   
[80］ ROBSON M, IM SA, SENKUS E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation [J]. N Engl J Med, 2017, 377 (6): 523-533.   
[81］ ROBSON ME, TUNG N, CONTE P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [J]. Ann Oncol, 2019, 30 (4): 558-566.   
[ 82 ] YUAN P, HU X, SUN T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial [J]. Eur J Cancer, 2019, 112: 57-65.   
[83 ］ HU XC, ZHANG J, XU BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, openlabel, multicentre, phase 3 trial [J]. Lancet Oncol, 2015, 16 (4): 436-446.   
[ 84 ］ SIPOS O, TOVEY H, QUIST J, et al. Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial [J]. Ann Oncol, 2021, 32 (1): 58-65.   
[85 ］ XU B, SUN T, ZHANG Q, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase $\Vert\Vert$ randomised controlled trial [J]. Ann Oncol, 2021, 32 (2): 218-228.   
[ 86 ］ BARDIA A, MAYER IA, VAHDAT LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triplenegative breast cancer [J]. N Engl J Med, 2019, 380 (8): 741-751.   
[87] ROBERTSON J F R, BONDARENKO I M, TRISHKINA E, et al. Fulvestrant 50O mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [J]. Lancet, 2016, 388 (10063): 2997-3005.   
[88 ］ FINN RS, MARTIN M, RUGO HS, et al. Palbociclib and letrozole in advanced breast cancer [J]. N Engl J Med, 2016, 375 (20): 1925-1936.   
[89 ] HORTOBAGYI GN, STEMMER SM, BURRIS HA, et al. Updated results from MONA-LEESA-2, a phase Ml trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptorpositive, HER2-negative advanced breast cancer [J]. Ann Oncol, 2018, 29 (7): 1541-1547.   
[90 ］ DI LEO A, JERUSALEM G, PETRUZELKA L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial [J]. J Natl Cancer Inst, 2014, 106 (1): djt337.   
[ 91 ] ZHANG Q, SHAO Z, SHEN K, et al. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China [J. Oncotarget, 2016, 7 (35): 57301-57309.   
[ 92 ] ELLIS M J, LLOMBART-CUSSAC A, FELTL D, et al. Fulvestrant 50O mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study [J]. J Clin Oncol, 2015, 33 (32): 3781-3787.   
[ 93 ］ CRISTOFANILLI M, TURNER NC, BONDARENKO I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J]. Lancet Oncol, 2016, 17 (4): 425-439.   
[ 94 ］ TURNER NC, SLAMON DJ, RO J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer [J]. N Engl J Med, 2018, 379 (20): 1926-1936.   
[ 95 ] SLEDGE GW JR, TOI M, NEVEN P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in Women With HR $^{+}$ /HER2- advanced breast cancer who had progressed while receiving endocrine therapy [J]. J Clin Oncol, 2017, 35 (25): 2875-2884.   
[ 96］ ZHANG QY, SUN T, YIN YM, et al. MONARCH plus: abemaciclib plus endocrine therapy in women withHR $^{+}$ /HER2- advanced breast cancer: the multinational randomized phase IMl study [J]. Ther Adv Med 0ncol, 2020, 12: 1758835920963925.   
[ 97] XU B, ZHANG Q, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptorpositive and HER2-negative advanced breast cancer: a randomized, phase 3 trial [J]. Nat Med, 2021, 27 (11): 1904-1909.   
[ 98］ JIANG Z, LI W, HU X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebocontrolled, phase 3 trial [J]. Lancet Oncol, 2019, 20 (6): 806-815.   
[ 99 ］ YARDLEY DA, NOGUCHI S, PRITCHARD KI, et al. Everolimus plus exemestane in postmenopausal patients with HR ( $^+$ ) breast cancer: BOLERO-2 final progression-free survival analysis [J]. Adv Ther, 2013, 30 (10): 870-884.   
[ 100 ] NIE H, YUAN Y, LI J, et al. Occurrence and distribution of bone metastatic breast cancer patients. Transl Breast Cancer Res, 2021, 2: 4.   
[ 101 ］  YAN M, OUYANG Q, SUN T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, singlearm, two-cohort, phase 2 trial [J]. Lancet Oncol, 2022: S1470-2045 (21) 00716-6.   
[ 102 ]  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: Myeloid growth factors [EB/OL].[2021-03-11]. htps://www. nccn. org/store/Profile/Profile. aspx?requiredid=1# myeloid growth factors.   
［103」中国临床肿瘤学会，中华医学会血液学分会.葱环类药物心脏毒性防治指南（2013年版)J.临 床肿瘤学杂志,2013,18(10):925-934.   
［104」王碧芸，葛睿，江泽飞，等.乳腺癌靶向人表皮生长因子受体2酪氨酸激酶抑制剂不良反应管 理共识[J].中华肿瘤杂志，2020,42(10):798-806.   
［105］江泽飞,李健斌.新型冠状病毒肺炎疫情下乳腺癌诊疗十个热点问题的思考[凹.中华医学杂 志,2020,100 (10): 721-723.   
[ 106 ］ LI J, WANG H, GENG C, et al. Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020 [J]. E Clinical Medicine, 2020, 26: 100503.   
[ 107] NIE J, WANG T, XU R, et al. 2021 Chinese expert consensus on coronavirus disease 2019 vaccination for breast cancer patients [J]. Transl Breast Cancer Res, 2: 34.   
[ 108 ］ XU F, SEPULVEDA MJ, JIANG Z, et al. Effect of an artificial intelligence clinical decision support system on treatment decisions for complex breast cancer [J]. JCO Clin Cancer Inform, 2020, 4: 824- 838.   
[109」李健斌，江泽飞.中国临床肿瘤学会人工智能决策系统(CSCOAI)的建立与应用[J].中华医学 杂志,2020,100 (6): 411-415.  